Background of the Alert On September 10, 2025, the Drug Regulatory Authority of Pakistan (DRAP) issued a rapid alert targeting unlicensed and unauthorized drug manufacturers. This decisive action follows a report from the Directorate of Drugs Control Punjab (DDCP), which identified a spurious drug product circulating in the market.

Identified Product and Manufacturer The product in question is PAYODEN Solution 60mL, containing Povidone-Iodine (1% w/v). It was allegedly produced by an unlicensed entity claiming to be M/s MSL Laboratories, located in the Industrial Area of Karachi. Laboratory testing conducted by the Drug Testing Laboratory in Punjab confirmed the product as spurious, lacking the active pharmaceutical ingredient necessary for therapeutic efficacy.

Health Risks and Public Safety Concerns DRAP has classified the product as falsified and dangerous, emphasizing that it was manufactured without regulatory oversight. The absence of active ingredients means the product offers no therapeutic value and poses significant risks to public health. These risks include:

  • Treatment failure
  • Disease progression
  • Potential life-threatening complications

Consumers are strongly advised to avoid using this product and to report any suspicious or unauthorized medicines to DRAP immediately.

Regulatory Action and Surveillance Measures DRAP has mobilized its Regulatory Field Force to conduct nationwide surveillance. The goal is to confiscate all stocks of the unregistered PAYODEN Solution and investigate its distribution channels. Pharmacists, chemists, and healthcare professionals are urged to:

  • Check inventory for the recalled product
  • Report supplier details to DRAP or Provincial Drug Control Departments
  • Ensure complete removal of the product from circulation

Guidance for Healthcare Professionals Healthcare providers should remain vigilant across all supply chains, especially in pharmacies and healthcare facilities. Any adverse reactions or quality issues linked to the PAYODEN Solution must be reported to national or provincial pharmacovigilance centers using the official Adverse Event Reporting Form.

Advice for Consumers Consumers should refrain from using PAYODEN Solution and consult their healthcare provider if they have already used it or experienced any side effects. Always purchase therapeutic goods from licensed pharmacies and verify the authenticity of products before use. If in doubt, seek guidance from a pharmacist or medical professional.

Conclusion This alert underscores the importance of strict pharmaceutical regulation and public awareness. DRAP’s swift action aims to protect citizens from the dangers of falsified medicines and reinforce the integrity of Pakistan’s healthcare system. Stay informed, stay safe, and report any suspicious drug activity to the appropriate authorities.